Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 4Phase NA 3Phase 2/3 3Phase 1/2 3Phase 1 3Phase 4 1

Status

Unknown 4Recruiting 4Not yet recruiting 3Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Neoplasms 7Carcinoma, Hepatocellular 6Neoplasm Metastasis 5Leukemia, Myeloid, Acute 5Colorectal Neoplasms 5Breast Neoplasms 5Stomach Neoplasms 4Rectal Neoplasms 4Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Hematologic Neoplasms 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Acute Kidney Injury 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1

Interventions

Fluorouracil 2Cisplatin 2tislelizumab 1Paclitaxel 1Clinical Trials, Phase II as Topic 1Chemoradiotherapy 1Capecitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Esophageal Squamous Cell Carcinoma × Clear all
NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
90 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07251062 2025-11-26

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2/3 Not yet recruiting
737 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06861777 2025-03-11

Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Not yet recruiting
474 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡